8-K: Immix Biopharma Files Updated Auditor Consents for S-3
Auditor Consent Update
Immix Biopharma, Inc. filed an 8-K to include newly dated consents from its independent registered public accounting firms for its Form S-3 Registration Statement.
Summary
- Immix Biopharma, Inc. filed a Form 8-K to provide updated consents from its current and former independent registered public accounting firms.
- The consents are from Crowe LLP (current auditor) and KMJ Corbin & Company LLP (former auditor), both dated November 26, 2025.
- These consents are for the incorporation by reference of their audit reports into the Company's Registration Statement on Form S-3 (No. 333-290725).
- Crowe LLP's consent relates to the consolidated financial statements for the year ended December 31, 2024, as included in the Annual Report on Form 10-K filed March 25, 2025.
- KMJ Corbin & Company LLP's consent relates to the consolidated financial statements for the year ended December 31, 2023, also appearing in the Annual Report on Form 10-K for the year ended December 31, 2024.
- The consents also cover the reference to both firms under the "Experts" heading in the prospectus included in the Registration Statement.
Sentiment
Score: 5
Explanation: Neutral. This is a routine, procedural compliance filing with no direct positive or negative operational or financial implications.
Future Outlook
This filing is procedural and does not contain any forward-looking statements or guidance regarding the company's future operations or financial performance.
Industry Context
This is a standard compliance filing required by the SEC when an auditor's report is incorporated by reference into a new registration statement. It does not provide insights into broader industry trends or competitive landscape.
Stakeholder Impact
- Shareholders: Ensures continued compliance with SEC regulations regarding financial reporting and the effectiveness of the Form S-3 Registration Statement, which could be used for future capital raises impacting share structure.
Key Dates
| Date | Description |
|---|---|
| 2023-12-31 | Year-end for consolidated financial statements audited by KMJ Corbin & Company LLP. |
| 2024-03-29 | Date of KMJ Corbin & Company LLP's audit report for the year ended December 31, 2023. |
| 2024-12-31 | Year-end for consolidated financial statements audited by Crowe LLP. |
| 2025-03-24 | Date of Crowe LLP's audit report for the year ended December 31, 2024. |
| 2025-03-25 | Filing date of the Company's Annual Report on Form 10-K for the year ended December 31, 2024. |
| 2025-11-26 | Date of the current Form 8-K report and the newly dated consents from Crowe LLP and KMJ Corbin & Company LLP. |
Keywords
Immix Biopharma, IMMX, SEC Filing, Form 8-K, Auditor Consent, Crowe LLP, KMJ Corbin & Company LLP, Form S-3, Registration Statement, Financial Statements, Annual Report, Form 10-K
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.